House-dust mite allergy immunotherapy(Lofarma SpA)(House-dust mite allergy immunotherapy(Lofarma SpA)) - 在研适应症：哮喘，变应性结膜炎，过敏性鼻炎_专利_临床

概要

基本信息

药物类型

变应原提取物

别名-

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症

哮喘变应性结膜炎过敏性鼻炎

非在研适应症-

原研机构

Lofarma SpA

在研机构

Lofarma SpA

非在研机构-

最高研发阶段批准上市

首次获批日期

德国 (2018-01-01),

哮喘变应性结膜炎过敏性鼻炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 House-dust mite allergy immunotherapy(Lofarma SpA) 相关的临床结果

登录后查看更多信息

100 项与 House-dust mite allergy immunotherapy(Lofarma SpA) 相关的转化医学

登录后查看更多信息

100 项与 House-dust mite allergy immunotherapy(Lofarma SpA) 相关的专利（医药）

登录后查看更多信息

1

项与 House-dust mite allergy immunotherapy(Lofarma SpA) 相关的文献（医药）

1971-11-05·Drug and Therapeutics Bulletin

House-dust mite vaccines for hyposensitisation

Article

Rhinitis or asthma or both occur in some people because a specific reaginic antibody (IgE) develops after exposure to a particular allergen, for example house dust or grass pollen, and becomes attached to the surface of mast cells in nasal and bronchial tissue. Subsequent exposure of these tissue sites to the allergen and consequent interaction of allergen and reaginic antibody on the surface of mast cells results in their disruption with release of various substances which act on blood vessels and plain muscle and so cause the symptoms of asthma or rhinitis. Injections of successively increasing concentrations of the allergen (hyposensitisation) are widely used to treat these conditions. Where such treatment is effective it is suggested that the injections increase the plasma concentrations of ‘blocking’ antibody (IgG) specific for this allergen, so mopping up allergen that enters the body later and ‘blocking’ the union of allergen and IgE on the surface of mast cells, thus preventing the damaging reactions.

100 项与 House-dust mite allergy immunotherapy(Lofarma SpA) 相关的药物交易

登录后查看更多信息